A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression ; volume:160 ; number:2 ; day:5 ; month:10 ; year:2016 ; pages:249-259 ; date:11.2016
Breast cancer research and treatment ; 160, Heft 2 (5.10.2016), 249-259, 11.2016
- Creator
-
Reix, Nathalie
- Contributor
-
Malina, Charlotte
Chenard, Marie-Pierre
Bellocq, Jean-Pierre
Delpous, Stéphanie
Molière, Sébastien
Sevrin, Anthony
Neuberger, Karl
Tomasetto, Catherine
Mathelin, Carole
SpringerLink (Online service)
- DOI
-
10.1007/s10549-016-4000-z
- URN
-
urn:nbn:de:1111-2016111332210
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Reix, Nathalie
- Malina, Charlotte
- Chenard, Marie-Pierre
- Bellocq, Jean-Pierre
- Delpous, Stéphanie
- Molière, Sébastien
- Sevrin, Anthony
- Neuberger, Karl
- Tomasetto, Catherine
- Mathelin, Carole
- SpringerLink (Online service)
Other Objects (12)
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Mutant p53 gain of function induces HER2 over-expression in cancer cells
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Mutant p53 gain of function induces HER2 over-expression in cancer cells
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Mutant p53 gain of function induces HER2 over-expression in cancer cells
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer